<DOC>
	<DOCNO>NCT01714609</DOCNO>
	<brief_summary>Sorafenib approve US FDA treatment unresectable ( operate ) liver cancer renal cell carcinoma . Sorafenib drug inhibits growth cancer cell prevent formation new blood vessel would otherwise help cancer spread . Studies experimental animal show sorafenib may also lower portal vein pressure ( pressure blood pass intestine liver . ) This study seek determine sorafenib lower blood pressure liver blood vessel ( portal vein pressure ) patient cirrhosis high portal vein pressure . The study also obtain information whether sorafenib safe patient population . Half patient give sorafenib half give placebo ( pill without medicine . ) This allow comparison reaction people take sorafenib .</brief_summary>
	<brief_title>Pilot Study Effect Sorafenib Portal Pressure</brief_title>
	<detailed_description>This pilot proof-of-concept study investigates effect sorafenib portal pressure , determine hepatic venous pressure gradient ( HVPG ) , patient liver cirrhosis , portal hypertension unresectable hepatocellular carcinoma ( HCC ) successfully respond radiofrequency ablation and/or transarterial chemoembolization , obtain complete response . The primary end-point study change HVPG observe baseline three month start treatment sorafenib . Secondary end-point safety sorafenib . The trial structure randomize double blind placebo control study . After three-month period therapy sorafenib placebo ( double-blind phase ) , patient give open-label sorafenib additional 3-month period ( open-label phase ) . A total 44 patient randomize ( initial phase ) 1:1 ratio sorafenib placebo . Patients follow monthly HCC follow-up accord standard care . The study sponsor Onyx , also provide treatment medication ( sorafenib placebo )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age 2075 year Cirrhosis diagnose liver biopsy image study show nodular liver , splenomegaly and/or collateral HCC proven histologically diagnose follow AASLD criterion biopsy feasible refused patient HCC must unresectable within UCSF criterion ( single tumor ≤ 6.5 cm diameter , , multiple lesion , maximum diameter large lesion ≤ 4.5 total tumor diameter ≤ 8 cm ( 23 ) ) CPT score &lt; 9 ( Child A Child B score 7 8 ) Complete response treatment RFA ( include perform laparoscopically ) TACE combination define radiologic criterion ( hepatoma protocol MRI CT scan perform 46 week procedure ) . No two ablative procedure prior enrollment Presence portal hypertension , define HVPG &gt; 5 mmHg EGD variceal screening perform within 6 month entry study unless patient already stable dose non selective betablocker ( adjust obtain heart rate 5560 bpm ) treat variceal band ligation . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men use adequate birth control least three month last administration sorafenib . Signed informed consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>portal hypertension</keyword>
	<keyword>sorafenib</keyword>
</DOC>